This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Can Clinical Trials Collect Less Data Without Compromising Safety?
Rob DiCicco discusses how FDA–industry collaboration is helping sponsors rethink safety reporting, selective safety data collection, and pragmatic clinical trial design.
